Tango Therapeutics, Inc. (TNGX) Misses Q3 EPS by 7c

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.14), $0.07 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $53.81 million versus the consensus estimate of $53.8 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
• Intuit (INTU) PT Lowered to $370 at Freedom Broker
• Erste Group Starts Freeport-McMoRan (FCX) at Buy